Coherus Oncology (CHRS) Non-Current Debt (2016 - 2026)

Coherus Oncology has disclosed Non-Current Debt across 11 years of filings, most recently posting $37.1 million for Q1 2026.

• Non-Current Debt for Q1 2026 came in at $37.1 million, up 1.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $37.1 million (up 1.0% YoY), and the FY2025 annual result was $37.1 million, up 0.96% from the prior year.
• Non-Current Debt came in at $37.1 million for Q1 2026 at Coherus Oncology, roughly flat from $37.1 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $246.5 million in Q4 2023 to a low of $36.5 million in Q2 2024.
• The 5-year median for Non-Current Debt is $72.5 million (2024), against an average of $131.4 million.
• Across the five-year window, Non-Current Debt jumped 323.39% in 2022 and plunged 85.14% in 2024, its largest moves.
• Coherus Oncology's Non-Current Debt stood at $245.5 million in 2022, then increased by 0.41% to $246.5 million in 2023, then plunged by 85.11% to $36.7 million in 2024, then gained by 0.96% to $37.1 million in 2025, then increased by 0.26% to $37.1 million in 2026.
• The last three Non-Current Debt figures came in at $37.1 million (Q1 2026), $37.1 million (Q4 2025), and $37.0 million (Q3 2025), per Business Quant data.